compound tirzepatide uk COMPOUNDED Tirzepatide Research Peptide UK |

Type 2 diabetes mellitus 2

15 Phase II trials targeting MASH have shown that treatment with SEMA 0.4 mg daily for 72 weeks resulted in more patients with liver fibrosis stage F2/F3 achieving improvement in MASH without progression of liver fibrosis (odds ratio = 6.87, 95% CI = 2.6017.63) compared to placebo

How are the best results from semaglutide GLP-1 achieved

*After 68 weeks of weekly semaglutide treatment, participants experienced an average body weight reduction of 15%

However, gastrointestinal side effects from Mounjaro may affect your comfort during cosmetic procedures, and optimal diabetes control is advisable before elective treatments

These results have positioned Mounjaro as a leading treatment for obesity , now licensed in the UK for this indication